• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 2:39:21 PM ET
    $OXFD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OXFD alert in real time by email
    SC 13G/A 1 oxfda2_21621.htm CONSONANCE CAPITAL MANAGEMENT LP oxfda2_21621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    OXFORD IMMUNOTEC GLOBAL PLC
    (Name of Issuer)
    Ordinary Shares, 0.006705 nominal value per share
    (Title of Class of Securities)
    G6855A103
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: G6855A103
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: G6855A103
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Opportunity Fund Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    47-3018842
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: G6855A103
           
    1
    NAME OF REPORTING PERSON
    Mitchell Blutt
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    HC, IN
    CUSIP No.: G6855A103
           
    1
    NAME OF REPORTING PERSON
    Consonance Capman GP LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    HC, OO
    CUSIP No.: G6855A103
    ITEM 1(a). NAME OF ISSUER:
    OXFORD IMMUNOTEC GLOBAL PLC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom
    ITEM 2(a). NAME OF PERSON FILING:
    Consonance Capital Management LP
    Consonance Capital Opportunity Fund Management LP
    Mitchell Blutt
    Consonance Capman GP LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    1370 Avenue of the Americas
    Floor 33
    New York, NY 10019
    ITEM 2(c). CITIZENSHIP:
    Consonance Capital Management LP - Delaware USA
    Consonance Capital Opportunity Fund Management LP - Delaware USA
    Mitchell Blutt - USA
    Consonance Capman GP LLC - Delaware USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Ordinary Shares, 0.006705 nominal value per share
    ITEM 2(e). CUSIP NUMBER:
    G6855A103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    Consonance Capital Management LP - 0
    Consonance Capital Opportunity Fund Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0
    (b) Percent of class:
    Consonance Capital Management LP - 0%
    Consonance Capital Opportunity Fund Management LP - 0%
    Mitchell Blutt - 0%
    Consonance Capman GP LLC - 0%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    (ii) shared power to vote or to direct the vote:
    Consonance Capital Management LP - 0
    Consonance Capital Opportunity Fund Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0
    (iii) sole power to dispose or direct the disposition of:
    (iv) shared power to dispose or to direct the disposition of:
    Consonance Capital Management LP - 0
    Consonance Capital Opportunity Fund Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    The ownership information in Item 4 is incorporated herein by reference.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: G6855A103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 16 2021
    Consonance Capital Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Consonance Capital Opportunity Fund Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Mitchell Blutt
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Consonance Capman GP LLC
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: G6855A103
    Item 4. Ownership:
    This amendment is submitted to report that as of December 31, 2020, none of Consonance Capital Master Account LP (Consonance Master), Consonance Capital Opportunity Master Fund, LP (Consonance Opportunity Master), Consonance Capital Management LP (the investment adviser of Consonance Master, the Adviser), a managed account managed by Consonance Capital Opportunity Fund Management LP (Consonance Opportunity), Consonance Capman GP LLC (Capman), the general partner of the Adviser and Consonance Opportunity, and Mitchell Blutt, the Manager & Member of Capman and Chief Executive Officer of the Adviser, held any shares of the Issuers Common Stock.



    EXHIBIT 99.1
    JOINT FILING AGREEMENT
    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G, dated February 16, 2021 (including amendments thereto) with respect to the Ordinary Shares, 0.006705 nominal value per share of OXFORD IMMUNOTEC GLOBAL PLC. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

    CONSONANCE CAPITAL MANAGEMENT LP
    By: Consonance Capman GP LLC /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    CONSONANCE CAPITAL OPPORTUNITY FUND MANAGEMENT LP
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    MITCHELL BLUTT
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt

    CONSONANCE CAPMAN GP LLC
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member


    Get the next $OXFD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OXFD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OXFD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

      OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. T-SPOT®.COVID, a Test from Oxford Immunotec Global PLC for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infe

      3/4/21 2:26:00 PM ET
      $OXFD
      $PKI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea. Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit. Based on the Company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is

      2/8/21 9:15:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. The kit, for research use only, has been updated using the Company’s growing expertise of the T cell response to SARS-CoV-2 infection. The previous T-SPOT Discovery SARS-CoV-2 kit configuration included five antigen wells, each containing a mix of peptides representing target epitopes derived from the virus, with areas of high homology to endemic coronaviruses removed. Using the Company’s growing results database, it has

      2/4/21 9:15:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Leadership Updates

    Live Leadership Updates

    See more
    • PerkinElmer to Acquire Oxford Immunotec Global PLC

      WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordina

      1/7/21 7:00:00 AM ET
      $PKI
      $OXFD
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oxford Immunotec Global PLC

      SC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)

      5/7/21 5:05:21 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)

      3/8/21 5:05:38 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Oxford Immunotec Global PLC (0001586049) (Subject)

      2/17/21 3:14:15 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    SEC Filings

    See more
    • SEC Form 15-12B filed by Oxford Immunotec Global PLC

      15-12B - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/18/21 4:35:17 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/12/21 4:38:00 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/12/21 4:35:16 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:37:45 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:37:19 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:36:57 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Financials

    Live finance-specific insights

    See more
    • Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection. Based on the company’s T-SPOT technology, the only globally approved E

      12/2/20 9:00:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care